These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 24942334)
141. Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer. Kadowaki S; Kakuta M; Takahashi S; Takahashi A; Arai Y; Nishimura Y; Yatsuoka T; Ooki A; Yamaguchi K; Matsuo K; Muro K; Akagi K World J Gastroenterol; 2015 Jan; 21(4):1275-83. PubMed ID: 25632202 [TBL] [Abstract][Full Text] [Related]
142. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. Richman SD; Seymour MT; Chambers P; Elliott F; Daly CL; Meade AM; Taylor G; Barrett JH; Quirke P J Clin Oncol; 2009 Dec; 27(35):5931-7. PubMed ID: 19884549 [TBL] [Abstract][Full Text] [Related]
143. Cancer treatment and survivorship statistics, 2012. Siegel R; DeSantis C; Virgo K; Stein K; Mariotto A; Smith T; Cooper D; Gansler T; Lerro C; Fedewa S; Lin C; Leach C; Cannady RS; Cho H; Scoppa S; Hachey M; Kirch R; Jemal A; Ward E CA Cancer J Clin; 2012; 62(4):220-41. PubMed ID: 22700443 [TBL] [Abstract][Full Text] [Related]
144. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Ogino S; Shima K; Meyerhardt JA; McCleary NJ; Ng K; Hollis D; Saltz LB; Mayer RJ; Schaefer P; Whittom R; Hantel A; Benson AB; Spiegelman D; Goldberg RM; Bertagnolli MM; Fuchs CS Clin Cancer Res; 2012 Feb; 18(3):890-900. PubMed ID: 22147942 [TBL] [Abstract][Full Text] [Related]
145. Targeted therapies: how personal should we go? Martini M; Vecchione L; Siena S; Tejpar S; Bardelli A Nat Rev Clin Oncol; 2011 Nov; 9(2):87-97. PubMed ID: 22083042 [TBL] [Abstract][Full Text] [Related]
146. Data mining using the Catalogue of Somatic Mutations in Cancer BioMart. Shepherd R; Forbes SA; Beare D; Bamford S; Cole CG; Ward S; Bindal N; Gunasekaran P; Jia M; Kok CY; Leung K; Menzies A; Butler AP; Teague JW; Campbell PJ; Stratton MR; Futreal PA Database (Oxford); 2011; 2011():bar018. PubMed ID: 21609966 [TBL] [Abstract][Full Text] [Related]
147. Global cancer statistics. Jemal A; Bray F; Center MM; Ferlay J; Ward E; Forman D CA Cancer J Clin; 2011; 61(2):69-90. PubMed ID: 21296855 [TBL] [Abstract][Full Text] [Related]
148. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Fariña-Sarasqueta A; van Lijnschoten G; Moerland E; Creemers GJ; Lemmens VEPP; Rutten HJT; van den Brule AJC Ann Oncol; 2010 Dec; 21(12):2396-2402. PubMed ID: 20501503 [TBL] [Abstract][Full Text] [Related]
150. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. Roth AD; Tejpar S; Delorenzi M; Yan P; Fiocca R; Klingbiel D; Dietrich D; Biesmans B; Bodoky G; Barone C; Aranda E; Nordlinger B; Cisar L; Labianca R; Cunningham D; Van Cutsem E; Bosman F J Clin Oncol; 2010 Jan; 28(3):466-74. PubMed ID: 20008640 [TBL] [Abstract][Full Text] [Related]
151. Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis. Zlobec I; Bihl MP; Schwarb H; Terracciano L; Lugli A Int J Cancer; 2010 Jul; 127(2):367-80. PubMed ID: 19908233 [TBL] [Abstract][Full Text] [Related]
152. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. Van Cutsem E; Köhne CH; Hitre E; Zaluski J; Chang Chien CR; Makhson A; D'Haens G; Pintér T; Lim R; Bodoky G; Roh JK; Folprecht G; Ruff P; Stroh C; Tejpar S; Schlichting M; Nippgen J; Rougier P N Engl J Med; 2009 Apr; 360(14):1408-17. PubMed ID: 19339720 [TBL] [Abstract][Full Text] [Related]
153. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. Nosho K; Irahara N; Shima K; Kure S; Kirkner GJ; Schernhammer ES; Hazra A; Hunter DJ; Quackenbush J; Spiegelman D; Giovannucci EL; Fuchs CS; Ogino S PLoS One; 2008; 3(11):e3698. PubMed ID: 19002263 [TBL] [Abstract][Full Text] [Related]
154. Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies. Wong R; Cunningham D J Clin Oncol; 2008 Dec; 26(35):5668-70. PubMed ID: 19001346 [No Abstract] [Full Text] [Related]
155. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320 [TBL] [Abstract][Full Text] [Related]
156. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. Karapetis CS; Khambata-Ford S; Jonker DJ; O'Callaghan CJ; Tu D; Tebbutt NC; Simes RJ; Chalchal H; Shapiro JD; Robitaille S; Price TJ; Shepherd L; Au HJ; Langer C; Moore MJ; Zalcberg JR N Engl J Med; 2008 Oct; 359(17):1757-65. PubMed ID: 18946061 [TBL] [Abstract][Full Text] [Related]